Uzuka Takeo, Aoki Hiroshi, Natsumeda Manabu, Takahashi Hideaki, Fujii Yukihiko
Department of Neurosurgery, Niigata Cancer Center Hospital, Japan.
Neurol Med Chir (Tokyo). 2012;52(8):570-6. doi: 10.2176/nmc.52.570.
Elderly and low Karnofsky performance status (KPS) patients have been excluded from most prospective trials. This retrospective study investigated glioblastoma treatment outcomes, including those of elderly and low KPS patients, and analyzed the prognostic factors using the medical records of 107 consecutive patients, 59 men and 48 women aged from 21 to 85 years (median 65 years), with newly diagnosed glioblastoma treated at our institute. There were 71 high-risk patients with age >70 years and/or KPS <70%. Based on the extent of resection, the patients were classified into 3 groups: more than subtotal resection (subtotal, n = 44), partial resection (partial, n = 29), and biopsy only (biopsy, n = 34). Median overall survival (OS) of all 107 patients was 13.5 months. Median OS was 13.2 months in the high-risk group. Median OSs were 15.8, 12.8, and 12.1 months in the subtotal, partial, and biopsy groups, respectively. Multivariate analysis of 73 patients in the subtotal and partial groups found age ≤65 years (p = 0.047), 60 Gy irradiation (p = 0.009), O(6)-methylguanine-deoxyribonucleic acid methyltransferase-negative (p = 0.027), and more than subtotal removal (p = 0.003) were significant prognostic factors. The median postoperative KPS score tended to be better than the preoperative score, even in the high-risk group. We recommend maximal safe resection for glioblastoma patients, even those with advanced age and/or with low KPS scores.
大多数前瞻性试验都将老年患者和卡氏功能状态评分(KPS)较低的患者排除在外。这项回顾性研究调查了胶质母细胞瘤的治疗结果,包括老年患者和KPS评分较低患者的治疗结果,并利用我院收治的107例连续病例的病历分析了预后因素。这107例患者中,男性59例,女性48例,年龄21至85岁(中位年龄65岁),均为新诊断的胶质母细胞瘤患者。其中有71例高危患者,年龄>70岁和/或KPS<70%。根据切除范围,将患者分为3组:次全切除以上(次全切除,n=44)、部分切除(部分切除,n=29)和仅活检(活检,n=34)。107例患者的中位总生存期(OS)为13.5个月。高危组的中位OS为13.2个月。次全切除组、部分切除组和活检组的中位OS分别为15.8个月、12.8个月和12.1个月。对次全切除组和部分切除组的73例患者进行多因素分析发现,年龄≤65岁(p=0.047)、60 Gy放疗(p=0.009)、O(6)-甲基鸟嘌呤-脱氧核糖核酸甲基转移酶阴性(p=0.027)和次全切除以上(p=0.003)是显著的预后因素。即使在高危组,术后KPS评分中位数也往往优于术前评分。我们建议对胶质母细胞瘤患者进行最大安全切除,即使是高龄和/或KPS评分低的患者。